A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

NCT05909904 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer

Interventions

DRUG: Tislelizumab
DRUG: BGB-A425
DRUG: LBL-007

Sponsor

BeiGene